Open Label, Randomized, Single-dose, Cross-over Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Tablets, Administered to Adult Male and Female Patients With Chagas' Disease
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Nifurtimox (Primary)
- Indications Chagas disease
- Focus Pharmacokinetics
- Sponsors Bayer
- 06 Jan 2019 Status changed from active, no longer recruiting to completed.
- 05 Dec 2018 Planned End Date changed from 30 Nov 2018 to 14 Dec 2018.
- 09 Nov 2018 Planned End Date changed from 29 Jan 2019 to 30 Nov 2018.